吡格列酮和二甲双胍治疗对2型糖尿病患者血清抵抗素的影响

探讨吡格列酮和二甲双胍治疗对2型糖尿病患者血清抵抗素和胰岛素抵抗的不同影响。将48例初诊肥胖2型糖尿病患者随机分两组,分别给予二甲双胍（M组）和二甲双胍联合吡格列酮（MP组）治疗12周,于治疗前后测定受试者空腹血清抵抗素、血糖（FBS）、血脂、胰岛素（FINS）,测量身高、体重,计算体重指数（BMI）、胰岛素抵抗指数（HOMA-IR）。结果显示,与治疗前相比,MP组FBS、FINS、HOMA-IR、抵抗素水平明显降低（P〈0.01）;M组抵抗素水平没有明显改变（P〉0.05）,BMI、FINS、HOMA-IR水平明显降低（P〈0.01）。结论：吡格列酮治疗能有效降低肥胖2型糖尿病患者血清抵抗素水平。

Influence of Pioglitazone and Metformin Therapy on Serum Resistin in Patients with Type 2 Diabetes Mellitus

To investigate the influence of pioglitazone and metformin on serum resistin and insulin resistance in patients with type 2 diabetes mellitus.48 preliminary diagnosed patients with type 2 diabetes mellitus were randomized into two groups,which were treated with metformin（Group M） or pioglitazone and metformin（Group MP） for 12 weeks respectively.The fasten serum resistin,blood sugar（FBS）,blood fat and fast insulin（FINS）were measured before and after treatment.The height and weight of patients were measured to calculate body mass index（BMI）and insulin resistance index（HOMA-IR）.The results showed that the levels of FBS,FINS,HOMA-IR and serum resistin in group MP after treatment were decreased significant compared with before therapy（P0.01）.There was no difference on the levels of serum risistin before and after therapy in group M（P0.05）,while the levels of BMI,FINS and HOMA-IR were decreased significant after treatment in group M（P0.01）.The treatment with pioglitazone may decrease the level of serum resistin in fat patie.